Clinical Evaluation of BD NEXT Pen Needle

CompletedOBSERVATIONAL
Enrollment

217

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Interventions
DEVICE

BD NEXT 31G x 5 mm pen needle

Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.

DEVICE

BD NEXT 31G x 8mm pen needle

Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.

DEVICE

BD NEXT 32G x 4mm pen needle

Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.

Trial Locations (5)

23462

Corporation Lane Internal Medicine and Research Center, Virginia Beach

28803

Mountain Diabetes and Endocrine Center, Asheville

37660

Holston Medical Group, Kingsport

08755

Physicians Research Center, Toms River

M4G3E8

LMC Endocrinology Center, Toronto

Sponsors
All Listed Sponsors
lead

Becton, Dickinson and Company

INDUSTRY